


REMARKS

In the Examiner's Amendment attached to the Notice of Allowance dated October 19, 2006 (a copy of which is enclosed), the application was amended to replace the title. However, this amendment is not reflected in the Issue Fee Transmittal. Accordingly, Applicants hereby amend the title to agree with the Examiner's amendment.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 12-0080, under Order No. DCI-111.

Dated: January 4, 2007

Respectfully submitted,

By 
Jeanne M. DiGiorgio
Registration No.: 41,710
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jeanine DiGiorgio on 10/12/06.

The application has been amended as follows:

In The Title:

The title is replaced with the following:

----ISOLATED FERRIC REDUCTASE DEFECTIVE POLYPEPTIDES AND USES THEREOF----

In The Claims:

At claim 16, "biological sample" is replaced with ---medium---

In The Sequence Listing:

The sequence listings of 09/25/03 have been entered. However, the application does not comply the sequence Rule 1.821-1.825 because the sequences of Figure 13(A-C) lack sequence identifier (SEQ ID NO). The 37 CFR 1.821(d) requires the use of the assigned sequence identifier in all instances where the description or claims of a patent application discuss sequences. Examiner notes that the sequences of Figure are not included in the sequence listings of 09/25/03. For example, no sequences from

Art Unit: 1638

yeast or bacteria are provided in the sequence listings. Applicant must submit a new CRF and paper copy of the Sequence Listing, including the sequences of Figure 13. Applicant is also required to amend the specification (Under the Brief Description of the Drawings on page 10, line 26, before the period) to include the SEQ ID NO. See attached Notice To Comply Sequence Rule.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina A. Ibrahim whose telephone number is (571) 272-0797. The Examiner can normally be reached Monday -Thursday from 8:00AM to 5:30PM and every other Friday from 9:00AM to 5:00 PM. Before and after final responses should be directed to fax nos. (703) 872-9306 and (703) 872-9307, respectively.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

10/11/06

Mai

MEDINA A. IBRAHIM
PRIMARY EXAMINER

